The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Possible utility of actinin-4 as a predictive biomarker of the efficacy of postoperative adjuvant chemotherapy for completely resected early stage lung adenocarcinoma.
 
Hideaki Shiraishi
No Relationships to Disclose
 
Yutaka Fujiwara
Research Funding - AstraZeneca (Inst); Chugai Pharma (Inst); Eisai (Inst); GlaxoSmithKline (Inst); Lilly (Inst)
 
Takanori Kakuya
No Relationships to Disclose
 
Nami Miura
No Relationships to Disclose
 
Yukio Watabe
No Relationships to Disclose
 
Rintaro Noro
No Relationships to Disclose
 
Koji Tsuta
No Relationships to Disclose
 
Fumihiko Kakizaki
No Relationships to Disclose
 
Masahiro Kamita
No Relationships to Disclose
 
Hirokazu Shoji
No Relationships to Disclose
 
Wilber Huang
Patents, Royalties, Other Intellectual Property - WO2011/122634 (Inst)
 
Shun-ichi Watanabe
No Relationships to Disclose
 
Tesshi Yamada
Patents, Royalties, Other Intellectual Property - WO 2011/122634 (Inst)
 
Yuichiro Ohe
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Lilly
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Lilly; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Lilly (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
Expert Testimony - AstraZeneca
 
Kazufumi Honda
Research Funding - Abnova (Inst); Japan Agency for Medical Research and Development (Inst); Minimally Invasive Devices (Inst); Minimally Invasive Devices (Inst)
Patents, Royalties, Other Intellectual Property - WO2011/122634 (Inst)